Expression of microRNAs: Potential molecular link between obesity, diabetes and cancer

Obesity Reviews

Volumn 12, Issue 12, 2011, Pages 1050-1062

  Ali, A S ^a   Ali, S ^b   Ahmad, A ^a   Bao, B ^a   Philip, P A ^b   Sarkar, F H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Cancer; Diabetes; MicroRNA; Obesity

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA;

ANGIOGENESIS; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC MARKERS; HUMANS; MICRORNAS; NEOPLASMS; OBESITY;

EID: 81555203423     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00906.x     Document Type: Review

References (166)

1. Freedman DS. Obesity - United States, 1988-2008. MMWR Surveill Summ 2011; 60(Suppl.): 73-77.
2. Mooney H. British are the most overweight in Europe, new study shows. BMJ 2010; 341: c7225.
3. Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Clin 2001; 19: 459-470.
4. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
5. Beckles GL, Zhu J, Moonesinghe R. Diabetes - United States, 2004 and 2008. MMWR Surveill Summ 2011; 60(Suppl.): 90-93.
6. CDC. 2010. National Diabetes Surveillance System. Atlanta, GA: US Department of Health and Human Services. [WWW document]. URL (accessed 26 January 2011).
7. Mori Y, Hoshino K, Yokota K, Yokose T, Tajima N. Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men. Exp Clin Endocrinol Diabetes 2005; 113: 334-339.
8. Spellman CW. Pathophysiology of type 2 diabetes: targeting islet cell dysfunction. J Am Osteopath Assoc 2010; 110: S2-S7.
9. Dresslerova I, Vojacek J. Diabetes mellitus and ischemic heart disease. Vnitr Lek 2010; 56: 301-306.
10. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
12. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010; 3: 28-47.
13. Martin KR. Targeting apoptosis with dietary bioactive agents. Exp Biol Med (Maywood) 2006; 231: 117-129.
14. Davis CD, Emenaker NJ, Milner JA. Cellular proliferation, apoptosis and angiogenesis: molecular targets for nutritional preemption of cancer. Semin Oncol 2010; 37: 243-257.
15. Hjartaker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 2008; 630: 72-93.
16. Hillon P, Guiu B, Vincent J, Petit JM. Obesity, type 2 diabetes and risk of digestive cancer. Gastroenterol Clin Biol 2010; 34: 529-533.
17. Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 2010; 40: 323-332.
18. Ahmad A, Banerjee S, Wang Z, Kong D, Majumdar AP, Sarkar FH. Aging and inflammation: etiological culprits of cancer. Curr Aging Sci 2009; 2: 174-186.
19. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S etal. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta 2011; 1815: 135-146.
20. Satia JA, Campbell MK, Galanko JA, James A, Carr C, Sandler RS. Longitudinal changes in lifestyle behaviors and health status in colon cancer survivors. Cancer Epidemiol Biomarkers Prev 2004; 13: 1022-1031.
21. Wei EK, Wolin KY, Colditz GA. Time course of risk factors in cancer etiology and progression. J Clin Oncol 2010; 28: 4052-4057.
22. Lynch BM. Sedentary behavior and cancer: a systematic review of the literature and proposed biologic mechanisms. Cancer Epidemiol Biomarkers Prev 2010; 19: 2691-2709.
23. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol 2010; 47: 87-95.
24. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA etal. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674-1685.
25. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010; 28: 4086-4093.
26. Tran C, Gariani K, Philippe J. Insulin and cancer: myth or reality? Rev Med Suisse 2010; 6: 1188-1190, 1192.
27. Danne T, Bolinder J. New insulins and the risk of cancer. Int J Clin Pract Suppl 2010; 64(Suppl. s166): 26-28.
28. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004; 5: 153-165.
29. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K etal. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008; 300: 1523-1531.
30. Fenton JI, Birmingham JM, Hursting SD, Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 2008; 122: 2437-2445.
31. Vasseur F, Meyre D, Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev Mol Med 2006; 8: 1-12.
32. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. Cancer Res 2010; 70: 5430-5437.
33. Perrier S, Caldefie-Chezet F, Vasson MP. IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett 2009; 583: 259-265.
34. Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, Patel AV etal. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 2010; 70: 601-607.
35. Pierce BL, Ahsan H. Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 2010; 69: 193-201.
36. Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN etal. Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS ONE 2010; 5: e10858.
37. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K etal. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
38. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: D152-D157.
39. Lynn FC. Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 2009; 20: 452-459.
40. Heneghan HM, Miller N, Kerin MJ. Role of microRNAs in obesity and the metabolic syndrome. Obes Rev 2010; 11: 354-361.
41. Xie H, Sun L, Lodish HF. Targeting microRNAs in obesity. Expert Opin Ther Targets 2009; 13: 1227-1238.
42. Tang X, Tang G, Ozcan S. Role of microRNAs in diabetes. Biochim Biophys Acta 2008; 1779: 697-701.
43. Hennessy E, Clynes M, Jeppesen PB, O'Driscoll L. Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells. Biochem Biophys Res Commun 2010; 396: 457-462.
44. Tang X, Muniappan L, Tang G, Ozcan S. Identification of glucose-regulated miRNAs from pancreatic {beta} cells reveals a role for miR-30d in insulin transcription. RNA 2009; 15: 287-293.
45. Pandey AK, Agarwal P, Kaur K, Datta M. MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 2009; 23: 221-232.
46. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ, Liu ZM. MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract 2011; 91: 94-100.
47. Chen BZ, Yu SL, Singh S, Kao LP, Tsai ZY, Yang PC etal. Identification of microRNAs expressed highly in pancreatic islet-like cell clusters differentiated from human embryonic stem cells. Cell Biol Int 2011; 35: 29-37.
48. Bang-Berthelsen CH, Pedersen L, Floyel T, Hagedorn PH, Gylvin T, Pociot F. Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes. BMC Genomics 2011; 12: 97.
49. Sebastiani G, Vendrame F, Dotta F. MicroRNAs as new tools for exploring type 1 diabetes: relevance for immunomodulation and transplantation therapy. Transplant Proc 2011; 43: 330-332.
50. Ferland-McCollough D, Ozanne SE, Siddle K, Willis AE, Bushell M. The involvement of microRNAs in Type 2 diabetes. Biochem Soc Trans 2010; 38: 1565-1570.
51. Whittaker R, Loy PA, Sisman E, Suyama E, Za-Blanc P, Ingermanson RS etal. Identification of MicroRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening. J Biomol Screen 2010; 15: 798-805.
52. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle 2008; 7: 2485-2492.
53. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
54. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-179.
55. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009; 10: 578-585.
56. Erson AE, Petty EM. miRNAs and cancer: new research developments and potential clinical applications. Cancer Biol Ther 2009; 8: 2317-2322.
57. Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta 2010; 1805: 209-217.
58. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009; 69: 7495-7498.
59. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21: 2785-2794.
60. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J 2009; 276: 2348-2358.
61. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58: 1050-1057.
62. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 2008; 15: 341-355.
63. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C etal. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 2008; 3: e2557.
64. Wang Y, Lee CG. MicroRNA and cancer - focus on apoptosis. J Cell Mol Med 2009; 13: 12-23.
65. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J etal. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers 2009; 26: 27-34.
66. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K etal. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther 2010; 17: 398-408.
67. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007; 67: 6031-6043.
68. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-1920.
69. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M etal. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
70. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP etal. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer 2009; 100: 1002-1011.
71. Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT etal. The expression profile of microRNAs in a model of 7, 12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res 2009; 28: 64.
72. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 2009; 77: 12-21.
73. Clape C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F etal. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS ONE 2009; 4: e7542.
74. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S etal. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010; 64: 399-408.
75. Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep 2010; 24: 1363-1369.
76. Bockmeyer CL, Christgen M, Muller M, Fischer S, Ahrens P, Langer F etal. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res Treat 2011; EPUB ahead of print.
77. Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A etal. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 2010; 200: 154-160.
78. Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009; 50: 490-499.
79. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
80. Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ etal. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 2009; 101: 699-706.
81. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009; 276: 6689-6700.
82. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y etal. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther 2011; 19: 1123-1130.
83. Nakagawa Y, Iinuma M, Naoe T, Nozawa Y, Akao Y. Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem 2007; 15: 5620-5628.
84. Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich FT, Bronneke HS etal. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011; 13: 434-446.
85. Krupanidhi S, Sedimbi SK, Vaishnav G, Madhukar SS, Sanjeevi CB. Diabetes - role of epigenetics, genetics, and physiological factors. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34: 837-845.
86. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W etal. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630-2639.
87. Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells 2006; 24: 857-864.
88. Pierson J, Hostager B, Fan R, Vibhakar R. Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol 2008; 90: 1-7.
89. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L etal. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69: 4443-4453.
90. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M etal. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 2008; 7: 35.
91. Sun Y, Wu J, Wu SH, Thakur A, Bollig A, Huang Y etal. Expression profile of microRNAs in c-Myc induced mouse mammary tumors. Breast Cancer Res Treat 2009; 118: 185-196.
92. Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M etal. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J 2009; 276: 5537-5546.
93. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D etal. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
94. Khew-Goodall Y, Goodall GJ. Myc-modulated miR-9 makes more metastases. Nat Cell Biol 2010; 12: 209-211.
95. Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P etal. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010; 29: 5724-5728.
96. Joglekar MV, Parekh VS, Hardikar AA. New pancreas from old: microregulators of pancreas regeneration. Trends Endocrinol Metab 2007; 18: 393-400.
97. Joglekar MV, Joglekar VM, Hardikar AA. Expression of islet-specific microRNAs during human pancreatic development. Gene Expr Patterns 2009; 9: 109-113.
98. Scarola M, Schoeftner S, Schneider C, Benetti R. miR-335 directly targets Rb1 (pRb/p105) in a proximal connection to p53-dependent stress response. Cancer Res 2010; 70: 6925-6933.
99. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD etal. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
100. Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A etal. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 2011; 25: 226-231.
101. Esguerra JL, Bolmeson C, Cilio CM, Eliasson L. Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model goto-kakizaki rat. PLoS ONE 2011; 6: e18613.
102. Shchors K, Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res 2007; 67: 7059-7061.
103. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev 2003; 23: 117-145.
104. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
105. Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S etal. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat 2010; 122: 337-346.
106. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans 2009; 37: 1167-1170.
107. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011; 60: 1314-1323.
108. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D etal. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 2006; 1: e116.
109. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010; 285: 23457-23465.
110. Chan YC, Khanna S, Roy S, Sen CK. miR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J Biol Chem 2011; 286: 2047-2056.
111. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111: 1217-1226.
112. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111: 478-486.
113. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298-311.
114. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010; 42: 1282-1290.
115. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE etal. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226-230.
116. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008; 57: 2708-2717.
117. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P etal. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA 2009; 106: 5813-5818.
118. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y etal. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010; 20: 784-793.
119. de Souza Rocha SP, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R etal. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor {alpha} in breast cancer cells. Cancer Res 2010; 70: 9175-9184.
120. Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, Addis R etal. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011; 123: 282-291.
121. Sarkar S, Dey BK, Dutta A. MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Biol Cell 2010; 21: 2138-2149.
122. Jiang Q, Feng MG, Mo YY. Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 2009; 9: 194.
123. Sarkar FH, Li Y, Wang Z, Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008; 27: 293-319.
124. Sarkar FH, Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 2008; 13: 2950-2959.
125. Ahmad A, Sakr WA, Rahman KMW. Role of nuclear factor-kappa B signaling in anticancer properties of indole compounds. J Exp Clin Med 2011; 3: 55-62.
126. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets 2008; 9: 60-67.
127. Ruan H, Pownall HJ. The adipocyte IKK/NFkappaB pathway: a therapeutic target for insulin resistance. Curr Opin Investig Drugs 2009; 10: 346-352.
128. Patel S, Santani D. Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 2009; 61: 595-603.
129. Baker RG, Hayden MS, Ghosh S. NF-kappaB, inflammation, and metabolic disease. Cell Metab 2011; 13: 11-22.
130. Li Y, VandenBoom TG, Wang Z, Kong D, Ali S, Philip PA etal. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70: 1486-1495.
131. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009; 69: 1279-1283.
132. Kovacs B, Lumayag S, Cowan C, Xu S. microRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011; 57: 4402-4409.
133. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S etal. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 2010; 13: 109-118.
134. Ahmad A, Ali AS, Ali S, Wang Z, Kong D, Sarkar FH. MicroRNAs: targets of interest in breast cancer research. In: Mulligan JA (ed.). MicroRNA: Expression, Detection and Therapeutic Strategies. Nova Publishers: New York, 2011, pp. 59-78.
135. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G etal. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
136. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670-677.
137. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5: 115-119.
138. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 2009; 8: 843-852.
139. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S etal. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589.
140. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF etal. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-7854.
141. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR etal. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27: 1712-1721.
142. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA etal. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
143. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A etal. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15: 5060-5072.
144. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ etal. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23: 2140-2151.
145. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S etal. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS ONE 2010; 5: e12445.
146. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH. Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS ONE 2011; 6: e16068.
147. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W etal. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71: 3400-3409.
148. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I etal. miR-200 family controls {beta}-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2010; 18: 85-95.
149. Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM etal. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-3617.
150. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K etal. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2: ra62.
151. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 2010; 39: 761-772.
152. Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A etal. miR-200a prevents renal fibrogenesis through repression of TGF-{beta}2 expression. Diabetes 2011; 60: 280-287.
153. Joglekar MV, Patil D, Joglekar VM, Rao GV, Reddy DN, Mitnala S etal. The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets 2009; 1: 137-147.
154. Ozcan S. MiR-30 family and EMT in human fetal pancreatic islets. Islets 2009; 1: 283-285.
155. Fanjul M, Gmyr V, Sengenes C, Ratovo G, Dufresne M, Lefebvre B etal. Evidence for epithelial-mesenchymal transition in adult human pancreatic exocrine cells. J Histochem Cytochem 2010; 58: 807-823.
156. Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010; 31: 68-74.
157. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S etal. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS ONE 2011; 6: e17850.
158. Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010; 13: 57-66.
159. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010; 9: 306.
160. Zen K, Zhang CY. Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 2010; Nov 9 EPUB ahead of print.
161. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M etal. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
162. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y etal. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 2011; 48: 61-69.
163. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010; 118: 4-8.
164. Cannata D, Fierz Y, Vijayakumar A, Leroith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 2010; 77: 197-213.
165. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 24: 345-353.
166. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL etal. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.